Tumor
Conditions
Interventions
Research Group:Not involved
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients with malignant tumors confirmed by pathology; (2) Plan to receive at least one complete cycle of anti-tumor treatment regimens with moderate to high emetic risk (HEC/MEC) (including anti-tumor treatments with emetic risk such as chemotherapy, ADC therapy, TKIs, radiotherapy, CAR-T, etc., as well as their combination treatments); (3) Normal cognitive ability, capable of completing the patient diary records and scales required by the research (4) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Currently undergoing or about to receive treatment that may cause nausea and vomiting (except for anti-tumor treatment); (2) Combined with uncontrolled stable intracranial metastases; (3) Nausea/vomiting of any cause occurred within three days before enrollment; (4) Concurrent diseases that may cause nausea and vomiting; (5) There are obvious mental disorders, and the researcher determines that the study cannot be completed; Currently participating in other clinical trials; (6) Any situation where compliance is poor or the researcher determines that the study cannot be completed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of CINV throughout the entire cycle;Compliance rate of CINV prevention program guidelines; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of nausea symptoms throughout the entire cycle;There were no CINV days throughout the entire cycle;Quality of life assessment; | — |
Countries
China
Contacts
Public ContactZhu Jiang
West China Hospital, Sichuan University
Outcome results
None listed